AstraZeneca may have included outdated information from its COVID-19 vaccine clinical trial, the Data and Safety Monitoring Board said late Monday.
The outdated information may have provided an incomplete view of the efficacy data, the board said in notifying the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority and AstraZeneca.
